ClinicalTrials.gg
Not yet recruitingNCT07940621Updated Nov 17, 2026

Inotuzumab Plus Venetoclax in Older or Unfit Patients With Newly Diagnosed BCR::ABL1-Negative B-ALL

A Phase 2 interventional study of Inotuzumab Ozogamicin Plus Venetoclax Induction Therapy in Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP) and Acute Lymphoblastic Leukemia, Adult B-Cell, sponsored by Ruijin Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Ruijin Hospital · Phase 2, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This multicenter, open-label, prospective clinical study aimed to preliminarily investigate the efficacy and safety of inotuzumab ozogamicin combined with venetoclax as induction therapy in older patients with newly diagnosed B-cell acute lymphoblastic leukemia who are unfit for chemotherapy.

02

Conditions studied

  • Acute Lymphoblastic Leukemia
  • Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP)
  • Acute Lymphoblastic Leukemia, Adult B-Cell
03

In context

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.

This study's planned enrollment of 35 is below the median of 40 across 1,952 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Lead sponsor

Ruijin Hospital is the lead sponsor of 680 studies on the registry; 388 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed Ph/BCR::ABL1-negative B-cell acute lymphoblastic leukemia (B-ALL) according to the WHO 5th edition classification of haematolymphoid tumours;
  • CD22 protein expression on the surface of leukemic blasts >20%, as confirmed by flow cytometry or immunohistochemistry on pathological tissue;
  • The patient meets any one of the following conditions:

Age >65 years; Cardiac ≤50%, or very severe cardiovascular comorbidities such as congestive heart failure; Diffusing capacity of the lung for carbon monoxide (DLCO) ≤65% or (FEV1) ≤65%, or other severe pulmonary comorbidities; class B/C cirrhosis or transaminases >3 times the , or other severe hepatic comorbidities; The patient requires dialysis, or has other severe renal comorbidities; Active infection unresponsive to anti-infective therapy, or other severe infections; Psychiatric disorders requiring continuous specialized psychiatric treatment, or a dependent cognitive status that cannot be managed by the caregiver; performance status ≥3; Other uncontrolled ; Unsuitability for multi-agent combination chemotherapy due to severe thrombocytopenia (\<10×10\^9/L), severe neutropenia/agranulocytosis (\<0.5×10\^9/L), or other reasons; The patient refuses multi-agent combination chemotherapy for personal or other reasons; Other comorbidities that, in the investigator's judgment, make the patient unsuitable for multi-agent combination chemotherapy;

- Voluntary participation in this trial and provision of signed .

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years;
  • Diagnosis of mixed phenotype acute leukemia (MPAL), mature B-cell neoplasms (e.g., Burkitt lymphoma), or extramedullary disease at diagnosis;
  • Philadelphia chromosome detected by bone marrow cytogenetic testing, BCR::ABL1 fusion gene detected by molecular testing of bone marrow/blood, or chronic myeloid leukemia in blast crisis;
  • to inotuzumab ozogamicin or venetoclax;
  • Prior confirmed severe or persistent hepatic veno-occlusive disease (VOD), or severe persistent liver disease;
  • Requirement for life-support treatment, including vasopressors and invasive mechanical ventilation;
  • Pregnancy or lactation;
  • Any condition that, in the investigator's judgment, makes the patient unsuitable for enrollment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    intervention group

    Drug: Inotuzumab Ozogamicin Plus Venetoclax Induction Therapy

Interventions

  • DrugInotuzumab Ozogamicin Plus Venetoclax Induction Therapy

    One induction cycle consisted of fixed-dose INO (1 mg on days 1, 8, and 15), VEN (100 mg on day -2, 200 mg on day -1, and 400 mg on days 0-20), and MP (1 mg/kg from days -2 to 11, followed by a 2-week taper) The intensity of consolidation therapy was determined by leukemia burden. Patients achieving CR with MRD positivity received INO (1 mg on day 1 and 8) and VEN (400 mg daily on day 1-14). Those attaining MRD negativity received INO (1 mg on day 1) plus VEN (400 mg daily on day 1-7)

06

What researchers measure

Primary outcomes

  1. overall response rate

    Time frame: Till the end of the study, up to 24 months

Secondary outcomes

  1. minimal residual disease negativity rate

    Time frame: Till the end of the study, up to 24 months

  2. overall survival

    Time frame: Till the end of the study, up to 24 months

  3. Relapse-free survival

    Time frame: Till the end of the study, up to 24 months

  4. Hematological toxicity: neutropenia, thrombocytopenia, febrile neutropenia, anemia, bone marrow suppression Non hematological toxicity: SOS,TLS, peripheral edema, fever, fatigue, MODS, infection, liver dysfunction, renal dysfunction et al.

    Time frame: Till the end of the study, up to 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.

Of 209 non-industry phase 2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 120. This study's planned 24 months is below that.

Counting every sponsor, half of 227 studies reached it within 74 months; a quarter within 42 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Nov 11, 2026
Primary completionEst.
Nov 30, 2028
CompletionEst.
Nov 30, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940621
Lead sponsor
Ruijin Hospital
Responsible party
Jin Wang (Chief Physician, Ruijin Hospital) — Principal investigator
First posted
Nov 17, 2026
Start date
Nov 11, 2026 (estimated)
Primary completion
Nov 30, 2028 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Nov 17, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion